Funding News Edition: December 15, 2021 See more articles in this edition
NIAID seeks applications that can advance the molecular and genetic characterization of inborn errors of immunity through the Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity.
The overarching goal of this NOSI is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders.
Research Objectives and Scope
This NOSI prioritizes research on the following causes of inborn errors of immunity:
- Single nucleotide variants (inherited or de novo) in coding or non-coding regions of the genome
- Insertions or deletions (indels) in coding or non-coding regions of the genome
- Digenic/polygenic mutations
- Structural variations (large insertions or deletions, translocations, inversions, or copy-number variations)
Additionally, NIAID strongly encourages investigators to use state-of-the-art technologies and approaches (e.g., iPSC technology, CRISPR/Cas9 gene editing, multi-omics such as transcriptomics, proteomics, epigenetics) to accomplish the objectives of this NOSI. Applicants should finalize prioritization of putative disease-causing variant(s) before submission and present preliminary data to support causality between the variant(s) and disease phenotype. For single-patient studies, we strongly encourage adhering to the Guidelines for Genetic Studies in Single Patients: Lessons From Primary Immunodeficiencies.
Nonresponsive Areas of Research
If you propose research in the following areas, NIAID will consider the application nonresponsive and will not review it:
- Studies that propose the use of targeted gene sequencing panels, which analyze specific mutations known to cause inborn errors of immunity/primary immunodeficiency diseases, since they will not aid in identifying novel disease-causing mutations
- Characterization of somatic mutations
- Phenocopies of inborn errors of immunity/primary immunodeficiency diseases
- Applications that focus on HIV/SIV/AIDS
Application and Submission Information
This notice applies to due dates on or after February 5, 2022, and subsequent receipt dates through January 7, 2025.
Applicants can apply to this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice.
- PAR-20-185—NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed)
- PAR-20-195—NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed)
You must follow all instructions in the SF 424 (R&R) Application Guide and the FOA used for submission and the following additions:
- Applicants must include “NOT-AI-21-082” (without quotation marks) in the Agency Routing Identifier field box (box 4B) of the SF 424 R&R form to be considered for funding. Applications without this information in box 4B will not be considered for this initiative.
Direct any inquiries to Dr. Frosso Voulgaropoulou, NIAID’s scientific/research contact for this initiative, at 240-627-3205 or firstname.lastname@example.org.